BioSpace News Archive

The global orphan drug market is eminently competitive and fragmented in nature. There are several players in the market and a pool of new players is expected to enter the competitive global orphan drug market, states an upcoming Transparency Market Research report.

EdiGene, Inc. entered a non-exclusive, worldwide license agreement with Boston Children’s Hospital for intellectual property related to methods and compositions for increasing fetal hemoglobin levels by disrupting BCL11A expression at the genomic level to treat hemoglobinopathies.

Prothena Corporation plc presented new preclinical data from both its dual Aβ/tau vaccine for the potential treatment and prevention of Alzheimer’s disease and from its tandem C-terminal α-synuclein vaccine programs for the potential treatment and prevention of Parkinson’s disease and related synucleinopathies.

Boston Scientific Corporation announced that, pursuant to the previously announced cash tender offer for up to $2.5 billion aggregate principal amount of the outstanding senior notes identified in the table and the related notes below, $5,139,194,000 in aggregate principal amount of the Securities were validly tendered and not validly withdrawn on or prior to 5:00 p.m., Eastern Time, on March 15, 2022.

NuGen Medical Devices Inc., a leader in needle-free drug delivery, is pleased to announce that it has signed a 5-year distribution agreement with Harrington Consultants Limited and its joint venture partner Al Mufid Pharmaceuticals.

Soundbite Medical Solutions Inc. (SBMS), a medical device company leveraging its proprietary shock wave technology for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that members of its senior management team will participate in the 32nd Annual Oppenheimer Healthcare Conference.

Lunit, a leading startup in AI-based cancer solutions, announced today the publication of its study in the Journal of Clinical Oncology (JCO). Findings from the study validate the effectiveness of Lunit’s AI biomarker, Lunit SCOPE IO, in predicting clinical outcomes of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).

BioCorRx Inc. (OTCQB: BICX) (the “Company”), today announced it has received Independent Institutional Review Board (IRB) approval for the Company’s Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled R&D subsidiary.

Mountain Valley MD Holdings Inc. is pleased to announce the appointment of Dr. Elizabeth Norton to an advisory position to support MVMD’s key Quicksome™ vaccine and cold chain projects.

Strata Oncology, Inc., today announced enrollment of the first patient in the Strata Sentinel™ trial, a prospective, observational study that will evaluate the ability of the investigational StrataMRD™ test to detect cancer recurrence in advance of standard of care techniques across solid tumors.